Home
Choose language  
Pharmacoreport Pharmacoreport
www.pharmacoreport .com is a news site providing information about the top international pharmaceutical companies. This website will also provide other information about these pharmaceuticals like their address and locations, corporate history, clinical trials, annual report, employees, careers and jobs, health care products, research, sales, shares, dividend & stock price, and patients’ assistance program.
 
Genentech   Genentech

 


Genentech Inc, the amalgamation of Genetic Engineering Technology Inc is the foremost biotechnology enterprise which was established by the entrepreneur industrialist Robert A. Swanson in association with Dr. Herbert W. Boyer, during 1976, with the company’s headquarters situated at Southern San Francisco, California in the United States of America. One of the founders Dr. Boyer is believed to be amongst the pioneers in the sector of Recombinant DNA technology.

 

During 1973 Dr. Boyer in association with his colleague Stanley Norman Cohen, the Recombinant inherent engineering after understanding that restraint enzymes could be used as scissors for curtailing DNA fragments of interest from one source, to be ligated into the same cut plasmid vector. The company aims to be the foremost biotechnology enterprise using human genetic information for discovering, developing, producing and marketing bio-therapeutics that may help meeting vital challenging medical necessities.

 

Genentech is dedicated to maintain high standards of honesty in providing to the best interest of patients, the medical professionals and to all those connected for which the company is being consistently awarded or recognized for its ultimate performance as the enterprise, the administration, the working culture, contribution to the society and the patient support.  

 

Genentech has over 10,000 employees under the Chairmanship of Arthur D. Levinson, who is also the CEO of the company. Hoffmann-La Riche, the multinational Pharmaceutical group from Switzerland currently owns the majority of shares in Genentech Inc.

 

The major world renowned products of Genentech include:

Bio-Oncology: Avastin, Herceptin, Rituxan, Tarceva

Immunology: Raptiva, Rituxan, Xolair

Tissue Growth & Repair: Activase, Cathflo, Activase

Thrombolytic Agent: Lucentis

And so on.



Eishai Co , Merk and Co , Elcon , EEli Lilly and Company , Forast Laboratories , Amgemn , Schereeng , Johnsun and Johnsun , Metsubishi Pharma , Glaksosmithkline
Latest News About genentech
Genentech& closely watched cancer drug gets approval - MarketWatc...
MW) -- Genentech permission won USA on Thursday for its be named expected Avastin drugs, has increased been based ... Genentech $7.02, or 7 percent, to $103.10. .....More
Genentech Gets Another Approval
Anesthetize developer Genentech (NYSE: DNA) this strategy has pursued for most of its... Today Genentech received in the end formal permission to bring its breast on the market, .....More
Genentech optimistic about two medicines Benefits seen against vision...
Genentech inc. said, that Tuesday the early data positively for two experimentally. sind. Genentech released an abstract of Phasenii data to be submitted Oct. 26 on that.....More
Genentech Drops Nerve Drug For Diabetics After Tests Fail
Through DAVID J. MORROW Genentech inc. of one of the worldand most largely... Analysts said, that the setback a significant blow to Genentech and its majority stockholder. war...More
LEUKOSITE, GENENTECH FORM DEVELOPMENT DEAL
GENENTECH will be right worldwide to the proposed drug, that is expected, ... LEUKOSITE divides closed at 11 1/8, on 1/4; GENENTECH shares climbed 1/4 to 58 3/4.
More
Just the Boost Genentech Needs?
Then two years ago, it has drug in an attempt of Genentech Inc.and (DNA),. immatrikuliert. Genentech could use certainly the production that Raptiva would be allowed to furnish. .....More
GENENTECH BEGINS TESTING NEW DRUG, CD4, ON AIDS PATIENTS !
In September a GENENTECH rival to begin biogenously inc. of Cambridge, plans, its version of CD4 through de TO TESTING. Martin deer and Robert Schooley at.....More
Genentech Announces Manufacturing Agreements with Lonza
Simultaneously Genentech will register into a provision agreement for the manufacture of conscience Genentech products at Lonzaand arrangement momentarily under.....More
GENENTECH BREAKS EVEN
GENENTECH inc. has covered said Thursday it substantially the costs in the fourth quarter during... for the year, has GENENTECH $44.3 million, or 39 cents a share,. verdient...More
… General Corp. v. Genentech, Inc.,Bio-Technology General...
Genentech is is the direction receiver of two patents, that have references to hGH of that, at edition in this... Genentech sells encountered hGH and hGH under the trademark Protropin TM and.....More